000 | 03327nam a22005175i 4500 | ||
---|---|---|---|
001 | u373957 | ||
003 | SIRSI | ||
005 | 20160812084211.0 | ||
007 | cr nn 008mamaa | ||
008 | 101125s2011 gw | s |||| 0|eng d | ||
020 |
_a9783642111839 _9978-3-642-11183-9 |
||
040 | _cMX-MeUAM | ||
050 | 4 | _aRJ1-570 | |
082 | 0 | 4 |
_a618.92 _223 |
100 | 1 |
_aLaron, Zvi. _eeditor. |
|
245 | 1 | 0 |
_aLaron Syndrome - From Man to Mouse _h[recurso electrónico] : _bLessons from Clinical and Experimental Experience / _cedited by Zvi Laron, J. Kopchick. |
264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2011. |
|
300 |
_aXIV, 531p. 447 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
505 | 0 | _aFrom the Content: Part I - Laron Syndrome in Man -- Clinical Aspects -- History of the Israeli Cohort of Laron Syndrome Patients -- Early Investigations -- Clinical Evidence of Growth Hormone Resistance in Patients with Laron Syndrome -- Diagnosis of Laron Syndrome -- Genetic Aspects -- Clinical Evaluation -- Perinatal Evaluation -- Perinatal Development ;Laron Syndrome -- Linear Growth Pattern of Untreated Laron Syndrome Patients -- Head Shape, Size and Growth of Untreated Patients with Laron Syndrome -- Sexual Development in Patients with Laron Syndrome. | |
520 | _aLaron syndrome (LS), or primary growth hormone (GH) insensitivity, was first described in 1966. Since then, many patients worldwide have been diagnosed with LS, which involves defects in the GH receptor that cause combined congenital deficiency of GH and IGF-I activities. In this comprehensive book the authors draw upon 50 years of multidisciplinary clinical and investigative follow-up of the large Israeli cohort of LS patients. The genetic basis of the syndrome is fully considered, and all aspects of the pathophysiology of IGF-I deficiency are described. Data derived from the recently generated mouse model of LS are reviewed and compared with the human LS experience. Valuable advice is provided on treatment, and treatment effects, such as metabolic effects, adipose tissue alterations, and impact on aging, are fully explored. Together, this book condenses, consolidates, compares, and contrasts data derived from the human and mouse LS experiences and provides a unique resource for clinical and basic scientists to evaluate and compare IGF-I and GH actions. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aHuman genetics. | |
650 | 0 | _aHuman physiology. | |
650 | 0 | _aInternal medicine. | |
650 | 0 | _aEndocrinology. | |
650 | 0 | _aPediatrics. | |
650 | 1 | 4 | _aMedicine & Public Health. |
650 | 2 | 4 | _aPediatrics. |
650 | 2 | 4 | _aEndocrinology. |
650 | 2 | 4 | _aInternal Medicine. |
650 | 2 | 4 | _aHuman Genetics. |
650 | 2 | 4 | _aMolecular Medicine. |
650 | 2 | 4 | _aHuman Physiology. |
700 | 1 |
_aKopchick, J. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9783642111822 |
856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-3-642-11183-9 |
596 | _a19 | ||
942 | _cLIBRO_ELEC | ||
999 |
_c201837 _d201837 |